TWI811216B - 治療兒科病症之方法 - Google Patents

治療兒科病症之方法 Download PDF

Info

Publication number
TWI811216B
TWI811216B TW107114371A TW107114371A TWI811216B TW I811216 B TWI811216 B TW I811216B TW 107114371 A TW107114371 A TW 107114371A TW 107114371 A TW107114371 A TW 107114371A TW I811216 B TWI811216 B TW I811216B
Authority
TW
Taiwan
Prior art keywords
antibody
dose
weeks
seq
pediatric
Prior art date
Application number
TW107114371A
Other languages
English (en)
Chinese (zh)
Other versions
TW201842932A (zh
Inventor
瑪利亞 羅莎莉歐
麥可 A 斯特茲林
威廉 R 崔姆
Original Assignee
美商千禧製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商千禧製藥公司 filed Critical 美商千禧製藥公司
Publication of TW201842932A publication Critical patent/TW201842932A/zh
Application granted granted Critical
Publication of TWI811216B publication Critical patent/TWI811216B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1777—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW107114371A 2017-04-28 2018-04-27 治療兒科病症之方法 TWI811216B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762492031P 2017-04-28 2017-04-28
US62/492,031 2017-04-28

Publications (2)

Publication Number Publication Date
TW201842932A TW201842932A (zh) 2018-12-16
TWI811216B true TWI811216B (zh) 2023-08-11

Family

ID=62455814

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107114371A TWI811216B (zh) 2017-04-28 2018-04-27 治療兒科病症之方法
TW112126603A TW202342102A (zh) 2017-04-28 2018-04-27 治療兒科病症之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW112126603A TW202342102A (zh) 2017-04-28 2018-04-27 治療兒科病症之方法

Country Status (13)

Country Link
US (1) US20200179486A1 (https=)
EP (1) EP3615071A2 (https=)
JP (2) JP2020517671A (https=)
KR (2) KR20250134146A (https=)
CN (1) CN110612120A (https=)
AR (1) AR111491A1 (https=)
AU (2) AU2018256840A1 (https=)
BR (1) BR112019022268A2 (https=)
CA (1) CA3061320A1 (https=)
IL (1) IL270201B1 (https=)
MX (4) MX2019012749A (https=)
TW (2) TWI811216B (https=)
WO (1) WO2018200818A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
EP3956358A4 (en) * 2019-04-17 2023-01-25 Millennium Pharmaceuticals, Inc. COMBINATION THERAPY WITH ALPHA4BETA7 INHIBITOR AND IL-23 INHIBITOR
US20220408780A1 (en) * 2020-02-11 2022-12-29 The E. Wolfson Medical Center A method effective for treating ulcerative colitis
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2025177055A1 (en) * 2024-02-20 2025-08-28 Takeda Pharmaceutical Company Limited Combination therapy for treating inflammatory bowel disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151248A2 (en) * 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
EP0808367B1 (en) 1995-02-10 2007-07-11 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
US6939885B2 (en) 2002-11-18 2005-09-06 Chemocentryx Aryl sulfonamides
RS52213B (sr) 2004-09-03 2012-10-31 Genentech, Inc. Humanizovani anti-beta7 antagonisti i njihove primene
JP2009515552A (ja) 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
CN103382222B (zh) 2009-03-20 2016-12-28 安姆根有限公司 α-4-β-7异二聚体特异性拮抗剂抗体
DK3311834T3 (da) 2011-05-02 2026-04-20 Millennium Pharmaceuticals Inc Formulering til anti-alfa4beta7-antistof
KR20170120601A (ko) * 2015-02-26 2017-10-31 제넨테크, 인크. 인테그린 베타7 길항제 및 크론병을 치료하는 방법
BR112018068625A2 (pt) * 2016-03-14 2019-07-30 Millennium Pharm Inc métodos de tratamento ou prevenção de doença de enxerto contra hospedeiro

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012151248A2 (en) * 2011-05-02 2012-11-08 Millennium Pharmaceuticals, Inc. FORMULATION FOR ANTI-α4β7 ANTIBODY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 Namita Singh et al, " Multi-Center Experience of Vedolizumab Effectiveness in Pediatric Inflammatory Bowel Disease.", Inflamm Bowel Dis. 2016 Sep ;22(9):2121-6. *

Also Published As

Publication number Publication date
JP2020517671A (ja) 2020-06-18
IL270201B1 (en) 2026-01-01
EP3615071A2 (en) 2020-03-04
JP2023113655A (ja) 2023-08-16
AR111491A1 (es) 2019-07-17
TW202342102A (zh) 2023-11-01
IL270201A (https=) 2019-12-31
MX2024003906A (es) 2024-04-23
MX2024012972A (es) 2024-11-08
WO2018200818A3 (en) 2018-12-06
MX2019012749A (es) 2020-02-03
AU2025202525A1 (en) 2025-05-01
CA3061320A1 (en) 2018-11-01
WO2018200818A2 (en) 2018-11-01
RU2019138312A3 (https=) 2022-02-03
BR112019022268A2 (pt) 2020-05-19
US20200179486A1 (en) 2020-06-11
RU2019138312A (ru) 2021-05-28
WO2018200818A9 (en) 2019-01-17
MX2024003905A (es) 2024-04-23
CN110612120A (zh) 2019-12-24
KR20250134146A (ko) 2025-09-09
AU2018256840A1 (en) 2019-11-07
KR20190141148A (ko) 2019-12-23
TW201842932A (zh) 2018-12-16

Similar Documents

Publication Publication Date Title
US20240368263A1 (en) Optimized anti-tl1a antibodies
TWI811216B (zh) 治療兒科病症之方法
KR102148063B1 (ko) 베타7 인테그린 길항제를 투여하는 방법
JP6668461B2 (ja) 炎症性疾患の処置法
US11440965B2 (en) Anti-OX40 antibody
US20240309104A1 (en) Compositions comprising humanized antibodies to tnf-like ligand 1a (tl1a) and uses thereof
JP2016179979A (ja) Ｐｃｓｋ９アンタゴニスト
JP7512433B2 (ja) 抗ｐｄ－１抗体
JP2019528285A (ja) 抗ｎｋｇ２ｄ抗体を用いたクローン病の治療方法
CN114630680B (zh) 用于治疗乙型肝炎病毒感染的抗体组合物和方法
JP2019536756A (ja) Ｉｌ−２３ａ抗体を用いて疾患を処置する方法
JP7202893B2 (ja) 炎症性腸疾患を治療する方法
CN119768431A (zh) Igf1r抗体
RU2778567C2 (ru) Способ лечения педиатрических расстройств/заболеваний
US20230220053A1 (en) ANTI-SARS-CoV-2 ANTIBODIES AND USES THEREOF
HK40038976A (en) Isolated antibody or antigen binding fragment thereof and use of same in tumor treatment
HK40008722A (en) Methods of administering beta7 integrin antagonists